Morgan Stanley lowered the firm’s price target on UnitedHealth (UNH) to $325 from $342 and keeps an Overweight rating on the shares. The firm is lowering its estimates to reflect a more prolonged turnaround story, but notes that its “illustrative bridge” to 2027 EPS points to potential upside to Street estimates while acknowledging key variables in Medicare Star ratings as well as potential future regulatory and reimbursement shifts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Warren Buffett Makes ‘No-Brainer’ U-Turn Bet on UnitedHealth (UNH)
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Mixed options sentiment in UnitedHealth with shares down 0.91%
- Does Wall Street See Solid Upside in UnitedHealth Stock (UNH) after Buffett and Hedge Funds Bet Big?
- ‘Nothing Is OK’ Says Bank of America on UnitedHealth Stock (UNH) Despite Warren Buffett’s New Bet